5-(6-Quinolinylmethylene)-2-[(2-thienylmethyl)amino]-4(5H)-thiazolone
CAS: 872573-93-8
Rif. 3D-XJB57393
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione |
Informazioni sul prodotto
- Ro-3306
- (5Z)-5-(quinolin-6-ylmethylidene)-2-(thiophen-2-ylmethylamino)-1,3-thiazol-4-one
- 5-(6-Quinolinylmethylene)-2-[(2-thienylmethyl)amino]-4(5H)-thiazolone
- (Z)-5-(quinolin-6-ylmethylene)-2-(thiophen-2-ylmethylamino)thiazol-4(5H)-one
- 2-[[(Thiophen-2-yl)methyl]amino]-5-[1-(quinolin-6-yl)meth-(Z)-ylidene]thiazol-4-one
- (5Z)-5-Quinolin-6-ylmethylene-2-[(thiophen-2-ylmethyl)-amino]-thiazol-4-one
Quizartinib is a targeted inhibitor of the protein kinase A-Raf signaling pathway and is used for the treatment of certain types of cancer. Quizartinib inhibits the polymerase chain reaction, which can lead to cell death. It also has inhibitory properties on some cancer cells by targeting her2+ breast cancer cells and inhibiting tumor growth in vivo models. Quizartinib has been shown to be effective against autoimmune diseases such as lupus erythematosus, rheumatoid arthritis, and psoriasis. This drug also exhibits pluripotency markers that are similar to those found in embryonic stem cells.